Darling Ingredients Announces Publication of Peer-Reviewed Collagen Peptides Study and its Impact on Post-Meal Blood Glucose Spikes
Darling Ingredients (NYSE: DAR) has announced the publication of preclinical and clinical studies in the Wiley Journal of Food Science and Nutrition, focusing on the impact of a specific collagen peptide composition on post-meal blood glucose spikes. The studies involve Nextida GC™, the first product in Rousselot's Nextida library, which has shown significant potential in mitigating post-meal glucose spikes in healthy individuals.
In the clinical trial, participants who consumed 5- or 10-gram doses of Nextida GC 30 minutes before a meal experienced a 42% reduction in blood glucose spike on average after the meal. This research supports Darling Ingredients' commitment to developing new collagen-based products with health benefits beyond traditional ones, meeting the growing consumer demand for natural and effective health solutions.
Darling Ingredients (NYSE: DAR) ha annunciato la pubblicazione di studi preclinici e clinici nella Wiley Journal of Food Science and Nutrition, focalizzandosi sull'impatto di una specifica composizione di peptidi di collagene sui picchi di glucosio nel sangue post-pasto. Gli studi coinvolgono Nextida GC™, il primo prodotto della libreria Nextida di Rousselot, che ha dimostrato un potenziale significativo nel mitigare i picchi di glucosio post-pasto in individui sani.
Nella sperimentazione clinica, i partecipanti che hanno consumato dosi di 5 o 10 grammi di Nextida GC 30 minuti prima di un pasto hanno sperimentato una riduzione del 42% del picco di glucosio nel sangue in media dopo il pasto. Questa ricerca supporta l'impegno di Darling Ingredients nello sviluppo di nuovi prodotti a base di collagene con benefici per la salute oltre a quelli tradizionali, soddisfacendo la crescente domanda dei consumatori per soluzioni sanitarie naturali ed efficaci.
Darling Ingredients (NYSE: DAR) ha anunciado la publicación de estudios preclínicos y clínicos en la Wiley Journal of Food Science and Nutrition, centrándose en el impacto de una composición específica de péptidos de colágeno en los picos de glucosa en sangre después de las comidas. Los estudios involucran Nextida GC™, el primer producto de la biblioteca Nextida de Rousselot, que ha demostrado un potencial significativo para mitigar los picos de glucosa post-comida en individuos sanos.
En el ensayo clínico, los participantes que consumieron dosis de 5 o 10 gramos de Nextida GC 30 minutos antes de una comida experimentaron una reducción del 42% en el pico de glucosa en sangre en promedio después de la comida. Esta investigación respalda el compromiso de Darling Ingredients de desarrollar nuevos productos a base de colágeno con beneficios para la salud más allá de los tradicionales, atendiendo la creciente demanda de los consumidores por soluciones naturales y efectivas para la salud.
Darling Ingredients (NYSE: DAR)은 식사 후 혈당 급증에 대한 특정 콜라겐 펩타이드 조성의 영향을 집중한 전임상 및 임상 연구 결과를 Wiley Journal of Food Science and Nutrition에 발표했습니다. 이 연구는 Rousselot의 Nextida 라이브러리의 첫 번째 제품인 Nextida GC™를 포함하며, 건강한 개인에서 식사 후 혈당 급증을 완화하는 데 상당한 잠재력을 보여주었습니다.
임상 시험에서 참여자는 식사 30분 전에 5g 또는 10g의 Nextida GC를 섭취한 후 평균적으로 혈당 급증을 42% 감소시켰습니다. 이 연구는 Darling Ingredients가 전통적인 것 이상의 건강 이점을 가진 새로운 콜라겐 기반 제품을 개발하려는 의지를 지지하며, 자연적이고 효과적인 건강 솔루션에 대한 소비자의 증가하는 수요를 충족합니다.
Darling Ingredients (NYSE: DAR) a annoncé la publication d'études précliniques et cliniques dans le Wiley Journal of Food Science and Nutrition, se concentrant sur l'impact d'une composition spécifique de peptides de collagène sur les pics de glucose sanguin après les repas. Les études concernent Nextida GC™, le premier produit de la bibliothèque Nextida de Rousselot, qui a montré un potentiel significatif pour atténuer les pics de glucose après les repas chez des individus en bonne santé.
Lors de l'essai clinique, les participants ayant consommé des doses de 5 ou 10 grammes de Nextida GC 30 minutes avant un repas ont connu une réduction de 42% des pics de glucose sanguin en moyenne après le repas. Cette recherche soutient l'engagement de Darling Ingredients à développer de nouveaux produits à base de collagène avec des bienfaits pour la santé allant au-delà des produits traditionnels, répondant ainsi à la demande croissante des consommateurs pour des solutions de santé naturelles et efficaces.
Darling Ingredients (NYSE: DAR) hat die Veröffentlichung von präklinischen und klinischen Studien im Wiley Journal of Food Science and Nutrition bekannt gegeben, die sich auf die Auswirkungen einer bestimmten Kollagenpeptidzusammensetzung auf Blutzuckeranstiege nach dem Essen konzentrieren. Die Studien betreffen Nextida GC™, das erste Produkt aus der Nextida-Bibliothek von Rousselot, das ein erhebliches Potenzial zur Minderung von Blutzuckeranstiegen nach dem Essen bei gesunden Personen gezeigt hat.
In der klinischen Studie erlebten Teilnehmer, die 30 Minuten vor einer Mahlzeit 5- oder 10-Gramm-Dosen von Nextida GC konsumierten, im Durchschnitt eine Reduzierung des Blutzuckeranstiegs um 42% nach der Mahlzeit. Diese Forschung unterstützt das Engagement von Darling Ingredients, neue kollagenbasierte Produkte mit gesundheitlichen Vorteilen über die traditionellen hinaus zu entwickeln und der wachsenden Nachfrage der Verbraucher nach natürlichen und effektiven Gesundheitslösungen gerecht zu werden.
- Publication of preclinical and clinical studies in a peer-reviewed journal
- Nextida GC™ showed 42% reduction in post-meal blood glucose spikes
- Potential new product line addressing growing consumer demand for natural health solutions
- None.
Insights
The publication of this peer-reviewed study on Nextida GC™, a specific collagen peptide composition, represents a significant scientific advancement for Darling Ingredients. The research demonstrates a
However, it's important to note that while promising, this is still an early-stage development. The study was conducted on a small scale and further research will be needed to confirm these results and explore long-term effects. The market for blood sugar management supplements is competitive and it remains to be seen how Nextida GC™ will perform compared to existing products.
From an investor perspective, this development could potentially open new revenue streams for Darling Ingredients in the growing health supplements market. However, the path from research to commercialization can be long and uncertain. Investors should monitor for future updates on larger clinical trials, regulatory approvals and commercialization plans before factoring this into their valuation models.
Developed by Darling Ingredients' premier collagen and gelatin brand, Rousselot, the Nextida library features a groundbreaking collection of specific collagen peptide compositions with new targeted health benefits. The first product in this range, Nextida GC™, has shown significant potential in mitigating post-meal glucose spikes in healthy individuals.
This potential was confirmed in preclinical studies on mice and a proof-of-concept clinical study involving healthy individuals, including those with normoglycemia as well as prediabetes. In this first clinical trial, participants who consumed 5- or 10-gram doses of Nextida GC 30 minutes before a meal experienced a
"We are proud of this publication, which supports our discoveries, underscores the robustness of our scientific research, and highlights the potential of Nextida GC," said Randall C. Stuewe, Chairman and CEO, Darling Ingredients. "This product represents a significant breakthrough in the field of collagen peptides and offers a promising new option for individuals seeking safe and natural supplements to enhance their well-being."
As consumer demand for natural and effective health solutions continues to grow, Darling Ingredients is committed to leading the way in the development of new collagen-based products that offer health benefits extending beyond traditional ones.
About Darling Ingredients
A pioneer in circularity, Darling Ingredients Inc. (NYSE: DAR) takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about
Cautionary Statements Regarding Forward-Looking Information
This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals and strategies and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied by the forward-looking statements contained in this release. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.
Darling Ingredients Contacts | |
Investors: | Suann Guthrie |
Senior VP, Investor Relations, Sustainability & Communications | |
(469) 214-8202; suann.guthrie@darlingii.com | |
Media: | Jillian Fleming |
Director, Global Communications | |
(972) 541-7115; jillian.fleming@darlingii.com |
1 Grasset, E., et al., A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in 16 Healthy, Normoglycemic, and Prediabetic Humans. Wiley Journal of Food Science and Nutrition, Article ID: FSN34538, Article DOI: 10.1002/fsn3.4538, Inertanal Article ID: 100074727.
2 Reduced post-meal glucose spike by
View original content to download multimedia:https://www.prnewswire.com/news-releases/darling-ingredients-announces-publication-of-peer-reviewed-collagen-peptides-study-and-its-impact-on-post-meal-blood-glucose-spikes-302282196.html
SOURCE Darling Ingredients Inc.
FAQ
What is the main finding of Darling Ingredients' (DAR) collagen peptides study?
Where was Darling Ingredients' (DAR) collagen peptides study published?
What is Nextida GC™ developed by Darling Ingredients (DAR)?
How does Darling Ingredients' (DAR) Nextida GC™ potentially benefit consumers?
